Alamea Verwaltungs GmbH Invests $18.69 Million in GeneDx Holdings Corp. $WGS

Key Points

• Alamea Verwaltungs GmbH invested approximately $18.69 million in GeneDx Holdings Corp., acquiring 211,065 shares, making it the second largest holding in their portfolio.
• Several hedge funds increased their stakes in GeneDx during the first quarter, with Driehaus Capital Management boosting their investment by 40%, indicating strong institutional interest.
• Research analysts have adjusted their ratings for GeneDx, with Jefferies Financial Group and Wall Street Zen upgrading to a buy rating and setting target prices ranging from $80.00 to $120.00.

Alamea Verwaltungs GmbH purchased a new position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 211,065 shares of the company's stock, valued at approximately $18,693,000. GeneDx makes up about 16.2% of Alamea Verwaltungs GmbH's investment portfolio, making the stock its 2nd biggest holding. Alamea Verwaltungs GmbH owned about 0.75% of GeneDx as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. Ashford Capital Management Inc. bought a new position in GeneDx in the 1st quarter valued at approximately $8,344,000. Magnetar Financial LLC purchased a new stake in shares of GeneDx in the 1st quarter worth $555,000. Driehaus Capital Management LLC increased its stake in shares of GeneDx by 40.0% in the 1st quarter. Driehaus Capital Management LLC now owns 454,956 shares of the company's stock worth $40,293,000 after purchasing an additional 130,038 shares in the last quarter. Next Century Growth Investors LLC increased its stake in shares of GeneDx by 33.7% in the 1st quarter. Next Century Growth Investors LLC now owns 417,037 shares of the company's stock worth $36,935,000 after purchasing an additional 105,023 shares in the last quarter. Finally, FORA Capital LLC purchased a new stake in shares of GeneDx in the 1st quarter worth $420,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Jefferies Financial Group raised shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a report on Friday, May 9th. Wells Fargo & Company increased their price objective on shares of GeneDx from $78.00 to $95.00 and gave the company an "equal weight" rating in a report on Wednesday, July 30th. Wall Street Zen raised shares of GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Piper Sandler set a $120.00 price target on shares of GeneDx and gave the company an "overweight" rating in a report on Monday, August 4th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $115.00 price target (up previously from $88.00) on shares of GeneDx in a report on Monday, June 30th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, GeneDx presently has an average rating of "Moderate Buy" and a consensus target price of $101.63.

GeneDx Price Performance

Shares of WGS opened at $129.49 on Friday. The company has a market cap of $3.72 billion, a price-to-earnings ratio of 2,589.80 and a beta of 2.02. GeneDx Holdings Corp. has a twelve month low of $28.86 and a twelve month high of $130.91. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. The company has a 50 day moving average of $100.03 and a two-hundred day moving average of $89.62.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The business had revenue of $102.69 million during the quarter, compared to the consensus estimate of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. As a group, analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Insider Buying and Selling at GeneDx

In related news, CFO Kevin Feeley sold 5,278 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $93.00, for a total transaction of $490,854.00. Following the completion of the transaction, the chief financial officer directly owned 3,392 shares in the company, valued at $315,456. The trade was a 60.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Katherine Stueland sold 9,657 shares of GeneDx stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $90.94, for a total transaction of $878,207.58. Following the completion of the transaction, the chief executive officer directly owned 4,940 shares of the company's stock, valued at $449,243.60. The trade was a 66.16% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 561,633 shares of company stock valued at $67,530,714. Company insiders own 29.60% of the company's stock.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.